Autoradiographs of tissue slices from livers perfused with 1 x 10-9 M-1-O-[3H]octadecyl-2-acetyl-sn-glycero-3-phosphocholine ([3H]18:0-sn-3-AGEPC) indicate that binding of this agonist is localized in the portal venules in anterograde perfused livers, and in the central venules in retrograde perfused livers. The pattern of silver grains in anterograde perfused liver was not affected significantly by prior exposure to 100-fold excesses of unlabelled 16:0-or 18:0-sn-3-AGEPC, 16:0-sn-i-AGEPC, or a 1000-fold excess of U.66985.
INTRODUCTION
Platelet activating factor (1-O-alkyl-2-acetyl-glycero-3-phosphocholine, AGEPC) stimulates transient increases of glucose release, glycogen phosphorylase activation and portal pressure, and a transient decrease in hepatic oxygen consumption in the perfused rat liver (Shukla et al., 1983; Mendlovic et al., 1984; Buxton et al., 1984 Buxton et al., , 1986a . These responses are dose-dependent with a Ko5 of 2 x 1010M, require extracellular Ca2, show attenuation during successive exposure to the agonist and occur in the absence of appreciable changes in cyclic AMP, or ADP levels (Buxton et al., 1984 (Buxton et al., , 1986a . The hepatic responses to AGEPC are inhibited by the sn-3 modified analogue U.66985 (Buxton et al., 1986b) but not by the sn-I stereoisomer which is biologically inactive (Shukla et al., 1983) . In contrast, AGEPC does not increase significantly glucose release or phosphorylase activation (Fisher et al., 1984; Mendlovic et al., 1984) in suspensions of isolated hepatocytes. Further, in response to exposure to AGEPC, hepatocyte suspensions exhibit transient changes in phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 4-phosphate (Shukla et al., 1983; Fisher et al., 1984) in the absence of significant changes of inositol 1,4,5-trisphosphate levels (Charest et al., 1985) . These results have prompted the suggestion that the primary site of action of AGEPC in the liver is not at the hepatocyte.
The basic structural units of the liver include the portal vein and subsequent branches (portal venules), the sinusoids, central venules and veins, and lastly the hepatic vein (for review see Campra & Reynolds, 1982) . The sinusoids are immediately bounded by a layer of Kupffer and endothelial cells together comprising the reticuloendothelial system. These cells actively clear, by pino-and phagocytotic mechanisms, both biological (e.g. bacterial endotoxin and immune aggregates) and non-biological (e.g. carbon and latex particles) (Widmann et al., 1972; Wisse, 1977; Fahimi, 1982; PraaningVan Dalen & Knook, 1982) substances. This layer of cells separates the sinusoidal space from the hepatocytes. The walls of the venous system are also made up of cells of the reticuloendothelial system, and evidence from denatured albumin uptake experiments suggest that functional differences exist between periportal and perivenous endothelium (Yokota, 1985) . In addition, there is some evidence that Kupffer cells are located at a density gradient highest in sinusoids around the portal tract and lowest around the central veins (see Jones & Summerfield, 1982) . The suggestion has also been put forth that blood flow through the various sinusoids may be controlled by endothelial cells located at the junctions of portal or central venules and the sinusoids (McCuskey, 1966) . This report also showed that these cells have the potential to constrict or swell in response to some vasoactive substances. Potentially, AGEPC could bind at any or all of these sites. Identification of the primary Abbreviations used: the most specific form of naturally produced platelet activating factor has the structural formula of l-O-alkyl-2-acetyl-snglycero-3-phosphocholine. A simplified form of this name is sn-3-AGEPC, and this is used throughout the text with a notation as to the chain length of the alkyl residue. Other abbreviations used are: sn-l-AGEPC, 3-0-alkyl-2-acetyl-sn-glycero-1-phosphocholine; sn-3-lyso-GEPC, l-O-alkyl-snglycero-3-phosphocholine; U.66985, 1-0-octadecyl-2-acetyl-sn-glycero-3-phosphoric acid 6'-trimethylammonium hexyl ester. site of specific binding would create a clearer understanding of the mechanism of action of AGEPC in modifying hepatic haemodynamics and metabolism.
This study was initiated in an attempt to identify the location of AGEPC binding in the liver with the hope of clarifying the dichotomy of responses observed in the perfused liver and in isolated hepatocyte suspensions. We report here that the major portion of AGEPC binding in the liver is non-specific and is localized to the liver vasculature. In tandem with glucose release experiments performed using anterograde and retrograde perfused livers, and in suborganismic liver fractions, our results suggest further that the portal vasculature is a strong candidate for the site of specific binding of AGEPC.
EXPERIMENTAL Materials sn-3-AGEPC (1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) and sn-l-AGEPC (3-O-hexadecyl-2-acetyl-sn-glycero-1-phosphocholine) were purchased from Bachem, Bubendorf, Switzerland. [3H]18:0-sn-3-AGEPC (1-O-[10,1 1-3H]octadecyl-2-acetyl-sn-glycero-3-phosphocholine (67 Ci/mmol) was prepared by tritiation (New England Nuclear) of 1-O-(10,1 1-cis)-octadecenyl-2-acetyl-sn-glycero-3-phosphocholine (gift from Dr. D. E. Ayer, Lipids Research, The Upjohn Company, Kalamazoo, MI, U.S.A.). The corresponding deactylated derivative, [3H] 18: 0-sn-3-lyso-GEPC, was prepared by base-catalysed methanolysis of the parent compound. U.66985 (1-O-octadecyl-2-acetyl-sn-glycero-3-phosphoric acid 6'-trimethylammonium hexyl ester) was generously provided by Dr. D. E. Ayer. Latex microspheres (0.6 ,um diam, 2.5 % w/v) were from Polysciences Inc., phenylephrine was from Sigma, and bovine serum albumin (fatty acid free) was from Boehringer. All other materials were the highest quality available commercially.
Methods
Livers from male Sprague-Dawley rats (Houston facility of Harlan Sprague-Dawley, 150-200 g body weight fed ad libitum, and maintained on a 07:00-21:00 light cycle for 5-10 days) were perfused in situ with a non-recirculating perfusion system as described previously (Scholz et al., 1973) . The perfusate was Krebs- Henseleit bicarbonate-buffered saline (Krebs & Henseleit, 1932) (Ison & Sheridan, 1981 and placed on glass slides coated with Kodak NTB-2 nuclear tract emulsion. For each experimental condition the resulting autoradiographs were identical, and representative slides are illustrated. Preliminary experiments showed that the tissue could not be prepared for electron microscopic observation, as exposure to fixing and dehydrating agents resulted in complete removal of tissue-associated silver grains due to the lipophilic nature of AGEPC. After exposure for at least 3 weeks the slides were developed, stained with Toluidine Blue (0.1 % in water) and photographed at x 50 or x 250 magnification. In some experiments the livers were perfused with 16: 0-sn-1-AGEPC (1 x 10-7 M), U.66985 (1 x 10-6 M) or unlabelled 16:0-sn-3-AGEPC (1 x 10-7 M) after 35 min of perfusion. In others, unlabelled 16:0-sn-3-AGEPC (1 x 10-1 M) was infused over the intervals 35-37 and 45-47 min, followed by the infusion of labelled 18:0-sn-3-AGEPC at 55-57 min and tissue sampling as usual. In yet other experiments, [3H]16:0-sn-3-lyso-GEPC (17.5 Ci/mmol, I x 10-M) was infused instead of labelled AGEPC.
AGEPC conversion to its lyso-GEPC and alkylacyl-GPC metabolites was assayed in chloroform extracts of duplicate livers perfused, at 25°C, with 2 x 10-10 M-[3H] 18: 0-sn-3-AGEPC for 2 min followed by 8 or 28 min perfusion in the absence of AGEPC. Livers were freeze-clamped prior to extraction, and labelled lipids were analysed as described previously (Miwa et al., 1987) and expressed as fractions of the total label extracted.
Primary monolayers of hepatocytes and suspensions of liver slices were prepared as described previously, with the addition of 0.1 % bovine serum albumin in the final suspension medium . Glucose release from these preparations and perfused livers, in the absence or presence of 16:0-sn-3-AGEPC (1 x 10-9 or 1 x 1O-M) or phenylephrine (1 x 1O-' M), was measured using the method of Bergmeyer et al. (1974) . Glucose release is expressed as ,umol/h per g wet weight or as nmol/h per 60 mm culture dish. For perfusion experiments the amount of glucose released by agonists was expressed as the maximum observed change in rate above the basal rate of glucose release. All experiments were repeated at least twice. Means and S.E.M. are shown for the glucose release experiments.
RESULTS
Autoradiographs of tissue slices taken from livers exposed to [3H]AGEPC and then unlabelled perfusate for 0.5 min show that the highest density of silver grains is localized to the portal venule vasculature (Fig. la) . (Buxton et al., 1984) ], nor pre-exposure to U.66985 [at 1000-fold excess, which completely blocks AGEPC-stimulated glucose release (Buxton et al., 1986b) ], affect the distribution of grains illustrated in Fig. 1 13.8% (2.7) and 8.0% (1.1) of the total extracted label in AGEPC, lyso-GEPC and alkylacyl-GPC respectively. After a total of 28 min perfusion 31.3% (1.7), 33.3 (5.3) and 19.1 % (2.7) of the total label was found in the same materials. In addition the low concentration of [3H]sn-3-AGEPC used made it necessary to store the tissue slices on photographic emulsion for 16 weeks prior to development of the autoradiographs. The results show that exposure of the livers to increasing concentrations of bovine serum albumin resulted in decreased uptake of 3H during label infusion, increased washout of 3H and decreased the glucose release stimulated by AGEPC. With 1.25% albumin no stimulation of glucose release was detected, although about 30 % of the infused label was taken up by the livers. Examination of the autoradiographs of tissue slices obtained from biopsies of the same livers taken 0.5 min after perfusion in the absence of label showed that silver grains were present in the portal sinusoids in the absence of albumin (Fig. 2a) but not when 1.25% albumin was present (Fig. 2b) . With 0.25% albumin qualitatively similar results were obtained as those shown in Fig. 2(a) (not shown). These results suggest that specific binding sites, which result in the glycogenolytic response, are associated with the portal sinusoids.
In addition to the previous attempts to distinguish between specific and non-specific binding of AGEPC in the liver, [3H]sn-3-AGEPC was infused in the retrograde perfused liver. The autoradiographs illustrated in Fig. 3 show that the distribution of silver grains is the opposite of that seen in the anterograde perfusions. The highest density of grains is in the central venules (Fig. 3a) . There is some diffusion of grains into the surrounding parenchyma, indicating a higher degree of mobility of AGEPC in the retrograde compared with the anterograde perfused liver. The portal vasculature, arterioles and bile ducts contain a density of silver grains equivalent to background (Fig. 3b) .
In attempts to define more clearly the nature of AGEPC binding in the liver, and to determine whether a polarity of the hepatic response to AGEPC exists, the effect of AGEPC on glucose release was measured in anterograde and retrograde perfusions. Fig. 4 shows that infusion of sn-3-AGEPC (1 x 10-9 M) during retrograde perfusion does not stimulate a transient increase of glucose output. After a switch back to anterograde perfusion, AGEPC infusion stimulates a transient increase in glucose output, the peak of which is 115 ,umol/g per h above the basal glucose release. A transient increase of glucose release was always seen immediately following the initial switch from antero-to retrograde perfusion. This likely resulted from a transient decrease in 02 supply to the liver, since the effluent flow rate decreased by at least 50 % following the switch. In some instances a transient visible swelling of the livers paralleled the decrease in flow rate. Within 3-5 s complete recovery of the flow rate was attained. Observation of perfusion pressure also showed transient increases which recovered within 30 s to that observed prior to switching from antero-to retrograde perfusion (not shown). The switch response was variable in magnitude, with the experiment illustrated having the largest response observed. However, even with much lower switch responses stimulation of glucose release or portal pressure by AGEPC were not observed in retrograde perfusions.
The concentration-dependence of the glucose release stimulated by AGEPC indicates that the liver is affected significantly by the direction of perfusion flow (Fig. 5) known to act directly at the level of the hepatocyte, or initially at some other liver cell type. Fig. 6 shows that the response of the liver to phenylephrine, an aadrenergic agonist, is not affected by the direction of perfusate flow. In contrast, glucose release stimulated by latex particles shows a similar gradient of response as AGEPC, although the absolute magnitudes of these (endothelium free) and from suspensions of liver slices (non-perfused endothelium). Table 2 shows that the basal rates of glucose release were stimulated between 2 and 3-fold by the a-adrenergic agonist phenylephrine, but were not affected significantly by 1 or 100 mm-AGEPC. These results provide further evidence suggesting that the primary site of action of AGEPC in the liver is at the vascular endothlium.
DISCUSSION
This report presents visual and metabolic evidence which, in tandem, suggest that specific binding sites for platelet activating factor (sn-3-AGEPC) exist in the portal vasculature of the rat liver. Initial experiments designed to identify the location of sn-3-AGEPC binding in the liver indicate that the parenchyma, or nonvascular tissue, does not bind this compound, either specifically or non-specifically. This conclusion was reached from three lines of evidence. First, autoradiographs of this region do not show a density of silver grains above background levels. Second, exposure of the perfused livers to different concentrations of bovine serum albumin had no effect on the density of silver grains over the parenchyma. This was in contrast to the inhibitory effects of increasing concentrations of albumin on the density of silver grains over the portal sinusoids, and the glucose release in response to AGEPC. And last, the sensitivity of the liver to sn-3-AGEPC is reduced in retrograde compared with anterograde perfusions. Whereas this gradation of sensitivity contrasts with the response of the liver to agents which bind primarily to the hepatocyte membrane, it is similar to substances which interact with the reticuloendothelial system. These results corroborate previous reports which show that isolated hepatocyte suspensions, in contrast with the perfused liver, do not release glucose in response to exposure to sn-3-AGEPC (Buxton et al., 1984; Fisher et al., 1984; Mendlovic et al., 1984) . This lack of an effect may be due to loss or damage of hepatocyte receptors for AGEPC, as suggested previously (Fisher et al., 1984) . However, the observation that cultured monolayers of hepatocytes are insensitive to AGEPC indicates that specific receptors for AGEPC are not present in the hepatocyte plasma membrane.
Specific binding of a substance to a receptor is usually assessed by determining the displacement of binding of the labelled substance by an excess of the unlabelled substance. Binding of a substance is indicated as being non-specific when an excess of the unlabelled substance does not change the binding of the labelled substance. Specific binding can also be assessed by the induction of a biological response to the substance in question. Autoradiographs of liver slices exposed to [3H] 18: 0-sn-3-AGEPC show that it binds to the first tissue with which it comes in contact. In anterograde perfusions this is the periportal side, and in retrograde perfusions this is the retrograde side of the liver. In retrograde perfusions, this binding appears to be non-specific, as the biological response is greatly reduced. Although our results do not identify the mechanism involved in this decreased sensitivity of the retrograde perfused liver, it may result from a titration of non-specific binding sites in the perivenous vasculature. Since the distribution of silver grains in the retrograde perfusion showed significant diffusion into the parenchyma, it is most probable that the glycogenolytic response to high concentrations of AGEPC results from diffusion of ligand from the central venule, through the parenchyma and to the specific receptors in the portal sinusoids. However, the possibility cannot be excluded that the metabolic stimulation seen under these conditions arises from a non-specific interaction of micellar phospholipid with the hepatocyte membrane [the critical micellar concentration of sn-3-AGEPC is near 1 ,UM (Kramp et al., 1984) ].
Evidence presented in the communication also suggests that the majority of binding of platelet activating factor within the portal vasculature is non-specific, as the pattern of silver grains was not qualitatively modulated by prior treatment of the liver with unlabelled sn-3-AGEPC, sn-1-AGEPC or U.66985. In contrast both the density of silver grains within the portal vasculature and glucose release stimulated by AGEPC could be inhibited by bovine serum albumin. The apparent IO.5 for albumin of about 0.25 % for both binding of AGEPC and inhibition of a biological response in rabbit platelets (Yamashita et al., 1983) was similar to that seen in hepatic tissue (the present report). Further, since a biological response to sn-3-AGEPC was observed in the anterograde but not the retrograde perfusion, we conclude that specific binding sites are located in the portal vasculature, even though a large fraction of the observed binding is non-specific. This observation was not unexpected, as binding studies with platelets (Chesney et al., 1983) , and lung membrane preparations (Hwang et al., 1985) also show that between 70 and 90 % of [3H] 18:0-sn-3-AGEPC binding is non-specific (i.e. not displaceable with an excess of unlabelled sn-3-AGEPC).
Further evidence suggesting that AGEPC interacts specifically with the vascular endothelium comes from our observation that suspensions of liver slices, which contain both reticuloendothelial cells and hepatocytes, are unresponsive to AGEPC while retaining sensitivity to glycogenolytic agents which bind to the hepatocyte membrane. This result indicates that an intact and perfused vasculature is required for the ensuing biological responses of the liver to AGEPC. Parallel properties have been also reported for depolarizing gradients of potassium in the liver . Both the AGEPC and the potassium responses have been suggested to result from vasoconstriction of the vasculature leading to localized ischaemia within the hepatic parenchyma (Buxton et al., 1986a; . Although these reports showed that changes in the ATP/ADP ratio could not be detected in the perfused liver, we have recently shown that uric acid (and end-product ofadenine nucleotide metabolism) release increases with increased perfusate concentrations of potassium, indicating that large but localized decreases in perfusate oxygen concentrations occur within the liver .
We propose that exogenous sn-3-AGEPC administered in the perfused rat liver binds to a discrete cell type within the portal vascular endothelium, and that this binding results in the major metabolic and haemodynamic consequences of exposure of the liver to AGEPC.
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